I already gave a constructive critique. Small sample size. Common problem with clinical studies. Even if the study had resulted in positive results, it might not have been enough to convince the CMS, but no matter now.
Another problem with Ilfeld's RecoveryRx study might be that he included hernia repair. Remember how Koneru tried to tell the FDA that the ActiPatch worked better for women than for men, after the Koneru Brothers' study showed decent results for women but little effect for men?
Ilfeld didn't include hernia patients in the SofPulse study. Maybe he'll get better results.
Market Data 
Markets 
AI
